NRF2 expression level and estrogen function in BRCA1-mutated breast cancer

Breast cancer (BC) is the most common malignancy diagnosed in women, with approximately 5–10% of cases attributed to hereditary factors. Although the tumor suppressor breast cancer susceptibility gene 1(BRCA1) is ubiquitously expressed, it is not clear why BRCA1 mutations overwhelmingly predispose to breast and ovarian cancers. Estrogen has been proposed to promote the survival of BRCA1-deficient cells under oxidative stress by activating nuclear factor erythroid-2-related factor 2 (NRF2), potentially driving malignant transformation. This study investigates the role of estrogen and NRF2 expression in BRCA1-mutated breast cancer. We analyzed 70 formalin-fixed, paraffin-embedded (FFPE) tissue samples (tumor and adjacent non-tumoral) from 15 BRCA1-mutated breast cancer patients and 20 non-mutated controls. Both adjacent non-tumoral and tumoral breast tissue were paired samples from the same patient for the two groups. NRF2 expression was quantified using qRT-PCR, while estrogen activity was indirectly assessed via immunohistochemical (IHC) analysis of focal adhesion kinase (FAK) protein expression. NRF2 was significantly overexpressed in BRCA1-mutated tumors compared to controls (p = 0.036). In contrast, no significant difference in estrogen-mediated FAK expression was observed between BRCA1-mutated and control tumors. Our findings indicate that NRF2 upregulation is a distinguishing feature of BRCA1-mutated breast cancer, suggesting its potential involvement in tumorigenesis. These results offer new paths into targeted prevention and therapeutic strategies for BRCA1-mutation carriers.

• Publication year

  2025

• Venue

  BMC Cancer

• Publication date

  2025-10-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s12885-025-14781-xPMID 41120975PMCID 12542346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• Cancer statistics, 2024

  2024cited by this paper
• Mechanism of PARP inhibitor resistance and potential overcoming strategies

  2023cited by this paper
• NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.

  2023cited by this paper
• Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer.

  2023cited by this paper
• Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches

  2023cited by this paper
• AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells

  2023cited by this paper
• Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma

  2022cited by this paper
• Targeting NRF2 to Treat Cancer.

  2021cited by this paper
• The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism

  2021cited by this paper
• Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

  2020cited by this paper
• Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening

  2019cited by this paper
• NRF2 and the Hallmarks of Cancer.

  2018cited by this paper
• Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression

  2018cited by this paper
• Synergism between BRCA1 Mutation and Impaired Estrogen Signaling in Oxidative Stress Modulation Makes Estrogen Responsive Tissues (Breast) More Susceptible to Develop Cancer

  2018cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• BRCA1 as target for breast cancer prevention and therapy.

  2014cited by this paper
• Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway

  2014cited by this paper
• BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival

  2013cited by this paper
• Expression of Bmi-1 in Pediatric Brain Tumors as a New Independent Prognostic Marker of Patient Survival

  2013cited by this paper
• Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer

  2013cited by this paper
• The emerging role of the Nrf2–Keap1 signaling pathway in cancer

  2013cited by this paper
• Baseline E2 levels are higher in BRCA2 mutation carriers: a potential target for prevention?

  2013cited by this paper
• The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer☆

  2013cited by this paper
• The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.

  2013cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• High-grade serous ovarian cancer arises from fallopian tube in a mouse model

  2012cited by this paper
• Familial Breast Cancer

  2012cited by this paper
• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

  2010cited by this paper
• Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers

  2010cited by this paper
• BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications

  2010cited by this paper
• Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2

  2009cited by this paper
• Polygenic susceptibility to breast cancer: current state-of-the-art.

  2009cited by this paper
• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  2008cited by this paper
• Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase

  2007cited by this paper
• PTEN enters the nuclear age.

  2007cited by this paper
• A role of estrogen/ERα signaling in BRCA1-associated tissue-specific tumor formation

  2007cited by this paper
• Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.

  2007cited by this paper
• Estrogen receptors and human disease.

  2006cited by this paper
• Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations

  2006cited by this paper
• Estrogen carcinogenesis in breast cancer.

  2006cited by this paper
• Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway

  2006cited by this paper
• High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype

  2005cited by this paper
• Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

  2004cited by this paper
• Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A

  2004cited by this paper
• Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation

  2004cited by this paper
• BRCA1 Induces Antioxidant Gene Expression and Resistance to Oxidative Stress

  2004cited by this paper
• Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas

  2003cited by this paper
• Homologous repair of DNA damage and tumorigenesis:the BRCA connection

  2002cited by this paper
• Estrogens, BRCA1, and breast cancer.

  2000cited by this paper
• Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

  1999cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper

• No citing papers are available for this paper.